Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience RUO SARS-CoV-2 NGS Assay, Biotia COVID-Dx Software

Twist Bioscience has launched its research use-only SARS-CoV-2 next-generation sequencing assay.

The capture-based assay is for detection, characterization, and environmental monitoring of the virus from nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swabs, as well as nasopharyngeal wash/aspirates, nasal aspirates, and bronchoalveolar lavage specimens. It was validated on Illumina's NextSeq platform and includes Twist's synthetic SARS-CoV-2 RNA controls. The limit of detection is 800 viral copies/ml.

The test comes with COVID-Dx comprehensive data analysis software from Biotia, which provides an RUO report on the presence or absence of SARS-CoV-2 virus, the full sequence of the virus, genetic variants, and phylogenetic analysis.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.